A Randomized, Part A Partial Blinded and Part B Double Blinded, Placebo-controlled 24-week Clinical Study to Evaluate the Efficacy and Safety of Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase III

Latest Information Update: 13 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nomacopan (Primary) ; Corticosteroids
Indications Bullous pemphigoid
Focus Registrational; Therapeutic Use
Acronyms ARREST-BP
Sponsors Akari Therapeutics

Most Recent Events

07 Feb 2024 Planned End Date changed from 1 Jun 2025 to 1 Aug 2022.
07 Feb 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Aug 2022.
07 Sep 2022 Status changed from discontinued to withdrawn prior to enrolment due to strategic resource allocation decisions.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight